Study Enrollment


Your details will not be published or shared.

Clinical Trial

PRT811-01: A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Advanced Solid Tumors and Recurrent High-Grade Gliomas

This study is made up of two parts, Dose Escaltion, and Dose Expansion. Dose escalation is to test the safety of PRT811, at different dose levels and to find outwhat effects, good and/or bad, the study drug (PRT811) has on the subject and their type of cancer. The information collected from the subjects in this study when taking different dose levels will be used to decide the highest dose of the study drug that should be used in dose expansion and for other studies which may be completed in the future.


Eligibility Criteria

  • Subjects must be at least 18 years of age or older. Must have malignancies that are refactory to establish therapies know to provide clinical benefit for the malignancy in question, be intolerant of established therapies know to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies. All subjects should have malignancies that in the opinion of the Investigator require active treatment and are appropriate to enroll on a phase 1 study. Subjects must not have uncontrolled inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorbtion.

Contact Information

    Joanne Huff

    (706) 721-5177

   johuff@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.